These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

749 related articles for article (PubMed ID: 29604436)

  • 21. Tyrosine kinase inhibitors in HER2-positive breast cancer brain metastases: A systematic review and meta-analysis.
    Yu Y; Huang K; Lin Y; Zhang J; Song C
    Cancer Med; 2023 Jul; 12(14):15090-15100. PubMed ID: 37255389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brain metastases in breast cancer.
    Sim HW; Morris PG; Patil S; Khasraw M
    Expert Rev Anticancer Ther; 2014 Feb; 14(2):173-83. PubMed ID: 24308683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
    Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
    Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metastatic breast cancer: an updating.
    Nicolini A; Giardino R; Carpi A; Ferrari P; Anselmi L; Colosimo S; Conte M; Fini M; Giavaresi G; Berti P; Miccoli P
    Biomed Pharmacother; 2006 Nov; 60(9):548-56. PubMed ID: 16950593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy options for patients suffering from heavily pretreated metastatic breast cancer.
    Jerusalem G; Rorive A; Collignon J
    Future Oncol; 2015; 11(12):1775-89. PubMed ID: 26075446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
    Larsen PB; Kümler I; Nielsen DL
    Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic review of the management of brain metastases from hormone receptor positive breast cancer.
    Jusino S; Fadul CE; Dillon P
    J Neurooncol; 2023 Mar; 162(1):45-57. PubMed ID: 36884200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
    Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
    Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience.
    McKee MJ; Keith K; Deal AM; Garrett AL; Wheless AA; Green RL; Benbow JM; Dees EC; Carey LA; Ewend MG; Anders CK; Zagar TM
    Oncologist; 2016 Jan; 21(1):16-20. PubMed ID: 26659221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and acceptability of neoadjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: A network meta-analysis.
    Zhang T; Feng F; Yao Y; Qi L; Tian J; Zhou C; Dong S; Wang X; Sun C
    J Cell Physiol; 2019 Aug; 234(8):12393-12403. PubMed ID: 30652307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Review on the Management of Hormone Receptor-Positive Metastatic Breast Cancer.
    McAndrew NP; Finn RS
    JCO Oncol Pract; 2022 May; 18(5):319-327. PubMed ID: 34637323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
    Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
    J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
    Mangini NS; Wesolowski R; Ramaswamy B; Lustberg MB; Berger MJ
    Ann Pharmacother; 2015 Nov; 49(11):1252-60. PubMed ID: 26324355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
    Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
    Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
    Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
    Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
    López-Tarruella S; Jerez Y; Márquez-Rodas I; Echavarria I; Martin M
    Future Oncol; 2017 Oct; 13(24):2137-2149. PubMed ID: 28758424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
    Wilson FR; Varu A; Mitra D; Cameron C; Iyer S
    Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.
    Glück S; Castrellon A
    Am J Ther; 2009; 16(6):585-90. PubMed ID: 19287304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.